Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler; Hans Thorhauge Dam; R Gniadecki; Knud Kragballe; G B E Jemec; T Agner

doi:10.1111/j.1468-3083.2009.03202.x

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

K Ibler, Hans Thorhauge Dam, R Gniadecki, Knud Kragballe, G B E Jemec, T Agner

Dermato- & Venerologisk Afd.

24 Citationer (Scopus)

Abstrakt

Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).

Originalsprog	Engelsk
Tidsskrift	Journal of the European Academy of Dermatology and Venereology : JEADV
Vol/bind	24
Udgave nummer	7
Sider (fra-til)	837-9
Antal sider	3
DOI	https://doi.org/10.1111/j.1468-3083.2009.03202.x
Status	Udgivet - 1 jul. 2010

Adgang til dokumentet

10.1111/j.1468-3083.2009.03202.x

Citationsformater

@article{84148370ed4e4d0d9d11c3bd51063794,

title = "Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases",

abstract = "Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).",

author = "K Ibler and Dam, {Hans Thorhauge} and R Gniadecki and Knud Kragballe and Jemec, {G B E} and T Agner",

year = "2010",

month = jul,

day = "1",

doi = "10.1111/j.1468-3083.2009.03202.x",

language = "English",

volume = "24",

pages = "837--9",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "7",

}

TY - JOUR

T1 - Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

AU - Ibler, K

AU - Dam, Hans Thorhauge

AU - Gniadecki, R

AU - Kragballe, Knud

AU - Jemec, G B E

AU - Agner, T

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).

AB - Efalizumab is a recombinant humanized murine monoclonal antibody against CD11a, approved for the treatment of plaque psoriasis. However, recent reports suggest that it also may be effective in the treatment of severe atopic dermatitis (AD).

U2 - 10.1111/j.1468-3083.2009.03202.x

DO - 10.1111/j.1468-3083.2009.03202.x

M3 - Journal article

C2 - 19368612

VL - 24

SP - 837

EP - 839

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 7

ER -

Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases

Abstrakt

Adgang til dokumentet

Fingeraftryk

Citationsformater